Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.04−0.55 (-1.92%)
Close on Nov 17, 2026Market cap $2.20BP/E –Yield –
Celldex Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Celldex Therapeutics's price to sales ratio was 306.5× on Oct 31, 2025, against 208.1× a year earlier. Over the last 5 years it ranged from 7.9× to 476.9×, with a median of 219.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Oct 31, 2025 | 306.5× | +138.4 |
| 2024 | Dec 31, 2024 | 168.1× | −261.4 |
| 2023 | Dec 29, 2023 | 429.4× | +82.6 |
| 2022 | Jul 29, 2022 | 346.9× | +124.4 |
| 2021 | Dec 31, 2021 | 222.5× | +69.1 |
| 2020 | Dec 31, 2020 | 153.4× | +145.4 |
| 2019 | Dec 31, 2019 | 8.0× | +5.0 |
| 2018 | Dec 31, 2018 | 3.0× | −30.6 |
| 2017 | Dec 29, 2017 | 33.6× | −19.9 |
| 2016 | Dec 30, 2016 | 53.5× | −245.9 |
| 2015 | Dec 31, 2015 | 299.4× | −144.9 |
| 2014 | Sep 30, 2014 | 444.2× | +169.2 |
| 2013 | Dec 31, 2013 | 275.1× | +234.2 |
| 2012 | Dec 31, 2012 | 40.9× | +38.3 |
| 2011 | Dec 30, 2011 | 2.6× | −2.8 |
| 2010 | Dec 31, 2010 | 5.4× | – |
See a number that looks wrong?